Weight loss, bariatric surgery, and novel antidiabetic drugs effects on diabetic retinopathy: a review

• Published in: Current opinion in ophthalmology Vol. 35; no. 3; pp. 192 - 196
• Main Authors: Perez, Alejandro M, Neag, Emily, Sridhar, Jayanth, Williams, Jr, Basil K
• Format: Journal Article
• Language: English
• Published: United States 01-05-2024
• Subjects: Bariatric Surgery - adverse effects; Diabetes Mellitus - drug therapy; Diabetic Retinopathy - diagnosis; Humans; Hypoglycemic Agents - therapeutic use; Vision Disorders; Weight Loss
• ISSN: 1040-8738; 1531-7021
• DOI: 10.1097/ICU.0000000000001038

Diabetic retinopathy (DR) is a leading cause of visual impairment, and the increasing prevalence of diabetes and obesity will impact rates of visual impairment moving forward. Our review aims to synthesize the current body of evidence regarding the impact of lifestyle interventions, such as weight loss, bariatric surgery, and novel antidiabetic drugs, on DR.
Literature review revealed insufficient evidence regarding the impact of weight loss on DR. Preoperative DR patients undergoing bariatric surgery were found to have similar short-term chances of improvement or worsening DR. Progression of DR with glucagon-like peptide 1 receptor agonists treatments appears unrelated to specific drugs and was also observed with traditional antidiabetic medications.
Rapidly correcting HbA1c levels (≥2%) can paradoxically lead to early worsening DR. Patients considering weight loss, bariatric surgery, and novel antidiabetic drugs should be aware of the potential for DR progression, but they should not be discouraged, as achieving glycemic control is essential for reducing long-term morbidity and mortality from other diabetes-related complications. It is advisable to conduct a baseline retinal examination before treatment and continue monitoring during therapy. Further research is needed to understand the long-term effects of these treatments on DR.